Ultragenyx Pharmaceutical (RARE)
(Delayed Data from NSDQ)
$50.03 USD
-0.26 (-0.52%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $50.04 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
Ultragenyx Pharmaceutical Inc. [RARE]
Reports for Purchase
Showing records 41 - 60 ( 338 total )
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Upcoming Analyst Event Offers Closer Pipeline Look; In-Line Update For 2Q23
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
UX701 Pivotal Cyprus2+ Trial For Wilson Disease Advances Into Higher Dose; Initial Data Expected in 1H24; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Commercial Biotech Preview: Could 2Q23 Reporting Help Restart a Rally?
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
As Setrusumab Advances, Assigning Credit In Our Estimates
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains In Focus, As Will Crysvita Amidst Transition
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Commercial Biotech Preview: Let''s Get It Started
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Ultragenyx Pharmaceutical Inc.
Industry: Medical - Biomedical and Genetics
A Year of Both Execution and Transition for RARE [4Q22 RARE Highlights]
Provider: Wedbush Securities Inc.
Analyst: CHICO L